NDAORALTABLET
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENOVID is an oral contraceptive combining mestranol (estrogen) and norethynodrel (progestin), approved in 1961 as one of the first oral contraceptives marketed in the United States. It prevents pregnancy through suppression of ovulation and alteration of cervical mucus. ENOVID was historically a landmark product in women's reproductive health.
LOE Approaching
As a legacy product approaching loss of exclusivity, the brand team is likely in defensive/maintenance mode with limited growth investment and minimal headcount expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ENOVID presents minimal career growth opportunities due to its legacy status, approaching loss of exclusivity, and declining market position in a crowded contraceptive landscape. Professionals assigned to this product are typically managing decline rather than driving growth, which may limit advancement visibility.
Brand ManagerField Sales Representative
Worked on ENOVID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.